Bristol-Myers Squibb Co
NYSE:BMY
Relative Value
The Relative Value of one
BMY
stock under the Base Case scenario is
65.877
USD.
Compared to the current market price of 55.805 USD,
Bristol-Myers Squibb Co
is
Undervalued by 15%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
BMY Competitors Multiples
Bristol-Myers Squibb Co Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
113.4B USD | 2.4 | 18.8 | 6.7 | 8.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
985.1B USD | 16.6 | 53.5 | 35.9 | 38.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
554.2B USD | 5.9 | 20.7 | 14.4 | 17.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
283.2B CHF | 4.6 | 30.1 | 12.7 | 14.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.8B GBP | 5.1 | 31.6 | 15.1 | 22.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
224.7B CHF | 5.2 | 20.1 | 12.6 | 16.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
281.3B USD | 4.4 | 14.8 | 10.4 | 12.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK | 5.3 | 16 | 11.1 | 12.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.9B USD | 2.4 | 15.4 | 7.7 | 10.6 | |
| FR |
|
Sanofi SA
PAR:SAN
|
97.3B EUR | 1.7 | 8.2 | 7.6 | 7.6 |